triCitrasol by is a Prescription medication manufactured, distributed, or labeled by Citra Labs LLC, Citra Labs, LLC. Drug facts, warnings, and ingredients follow.
ANTICOAGULANT SODIUM CITRATE CONCENTRATE – 46.7% Trisodium Citrate
PN 6030, 30 mL
NDC: 23731-6030-3
triCitrasol® Anticoagulant Sodium Citrate Concentrate, 46.7% Trisodium Citrate, is a sterile, non-pyrogenic solution of Trisodium Citrate (Dihydrate), USP.
Each 30 mL of concentrate contains:
Trisodium Citrate, dihydrate, USP | 14.0 grams |
Water for Injection, USP | q.s. |
pH adjusted with Citric Acid
pH: 6.3 – 6.6
Single patient use only, on a single occasion.
triCitrasol® Anticoagulant Sodium Citrate Concentrate, 46.7% Trisodium Citrate, is an anticoagulant used in granulocytapheresis procedures (granulocyte collection by apheresis). Just prior to performing granulocytapheresis, aseptically add 30 mL of triCitrasol® to 500 mL of the 6% solution of Hydroxyethyl Starch (HES), e.g. Hespan ® 2-8. Agitate the resultant solution for 1 minute to assure a uniform concentration of anticoagulant. The resultant solution of triCitrasol® and 6% solution of HES contains the following concentration depending upon the volume used:
Volume of triCitrasol® | Volume of HES | Total Volume | Final Concentration of triCitrasol® |
---|---|---|---|
30 mL | 500 mL (measured from HES bag) | 530 mL | 2.6% |
30 mL | 558 mL (injected directly into HES bag) | 588 mL | 2.4% |
The triCitrasol®/HES solution is stable for up to 24 hours at room temperature after mixing.
Refer to the manufacturer's Operator's Manual of the apheresis medical device for the directions to perform the granulocytapheresis procedure.
Aseptic technique must be maintained at all times.
triCitrasol® Anticoagulant Sodium Citrate Concentrate is a clear/colorless solution. If the product shows any cloudiness or turbidity, the concentrate should be discarded.
The cap/stopper system provides a biological barrier and should be intact – discard product if system is comprised.
There are no adverse reactions for the addition of the product to the rouleaux agent.
Long-term studies in animals have not been performed to evaluate the carcinogenic potential of triCitrasol®.
Citrate reactions or toxicity may occur with the infusion of blood products containing citrate anticoagulant 1. 9 11. The recipient of the citrated blood product should be monitored for the signs and symptoms of citrate toxicity 1. 9 11. The signs and symptoms of citrate toxicity begin with paresthesia, a "tingling" sensation around the mouth or in the extremities, followed by severe reactions that are characterized by chills, stomach cramps, or pressure in the chest, followed by more severe reactions that are characterized by hypotension and possible cardiac arrhythmia 1. 9 11. Citrate toxicity may occur more frequently in patients that are hypothermic 10, have impaired liver or renal function 10, or have low calcium levels because of an underlying disease 9.
Since the bottle of triCitrasol® contains only 30mL of the product, it is impossible to overdose the addition of the product to the 6% solution of HES. However, in the event of a reaction to the infusion of citrated blood products, evaluate the patient and institute appropriate corrective actions 1, 9.
triCitrasol®
ANTICOAGULANT SODIUM CITRATE CONCENTRATE
46.7% Trisodium Citrate
PN 6030 - 30 mL
WARNING: CONCENTRATED ANTICOAGULANT
Dilute prior to use
NOT FOR DIRECT INTRAVENOUS INFUSION
THIS CARTON CONTAINS
10 Sterile Units - 30 mL each
Used with 6% Hydroxyethyl Starch 500 mL (diluent) for the Collection of
Granulocytes by Apheresis. Do not use for other anticoagulant purposes.
See package insert for directions for use.
Manufactured & Distributed by:
Citra Labs™
55 Messina Drive, Braintree, MA 02184 USA
Phone Number: 1-800-299-3411
Fax Number: 781-848-6781
Sterile ■ Non-Pyrogenic
Composition per 30 mL of Concentrate:
Trisodium Citrate (Dihydrate), USP 14.0 g
(pH adjusted with Citric Acid)
CAUTION: Single Procedure Use - Discard Unused Portion
Do Not Use Unless Solution is Clear and Seal is intact
Store Between 15°C - 30° C (59° F - 86° F)
Rx only
Exp:
Lot:
LA6030-10B 5/15
TRICITRASOL
trisodium citrate dihydrate solution |
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
Labeler - Citra Labs LLC (962863838) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
Citra Labs, LLC | 962863838 | manufacture(23731-6030) |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
TRICITRASOL 76301357 2739619 Live/Registered |
CITRA LABS, LLC 2001-08-16 |
TRICITRASOL 74348366 1797494 Dead/Cancelled |
CYTOSOL LABORATORIES, INC. 1993-01-14 |